<DOC>
	<DOCNO>NCT00065429</DOCNO>
	<brief_summary>This study Phase I/II trial primarily focus efficacy BB-10901 relapse small cell lung cancer solid tumor .</brief_summary>
	<brief_title>Safety Study Using Weekly Infusions BB-10901 Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>The Phase II efficacy expansion restrict SCLC patient relapse disease MTD determine Phase I portion trial ( 60mg/m2 ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Inclusion : Histologically Cytologically proven SCLC , CD 56+ small cell carcinoma unknown origin , CD56+ nonpulmonary small cell carcinoma Relapsed disease ; define patient initial response ( partial complete ) firstline therapy , relapse 3 month completion last chemotherapy . Patients must receive 3 prior chemotherapy regimen . Patients must measurable disease define : Lesions measure least one dimension accord RECIST Predicted survival 3 month Zubrod performance status 02 Patients must receive chemotherapy radiation therapy within 4 week study entry , plan surgery . Absolute neutrophils great equal 1.5 x 10^9/l , hemoglobin great equal 9g/dl platelet great equal 100 x 10^9/l . Creatinine le equal 1.5 time upper limit normal AST/ALT le equal 3 time upper limit normal without liver metastasis ; le equal 5 time upper limit normal liver metastases bilirubin less equal 1.5 time upper limit normal . Patients must normal thyroid function ( patient receive thyroxin replacement therapy biochemically euthyroid may enrol ) . Women childbearing potential must provide negative pregnancy test screening use adequate contraception opinion investigator , duration study . Patients must capable understanding nature trial must give write witnessed informed consent prior screening procedure . Exclusion : Significant residual neurological cardiac toxicity ( grade 3 4 ) follow previous chemotherapy Patients concurrently receive antineoplastic treatment ( chemotherapy , radiotherapy , immunotherapy include steroid therapy ) . Myocardial infarction within 6 month study entry , unstable angina pectoris , uncontrolled congestive heart failure , uncontrolled arrythmia , severe aortic stenosis , history multiple sclerosis , demyelinate disease , EatonLambert Syndrome , history hemorrhagic stroke , CNS injury residual neurologic deficit , ischaemic stroke within last 6 month , current know herpes zoster ( shingle ) , cytomegalovirus infection , history recurrent infection virus , chronic alcoholism , serious concomitant infection , concomitant illness consider significant enough interfere study outcome . Other investigational agent must take study within 4 week study entry . Previous monoclonal antibody therapy Patients must know central nervous system metastases Previous malignancy &lt; 5 year disease free interval last therapeutic intervention , except adequately treat basal cell carcinoma skin carcinoma situ cervix . Patient unwilling unable tolerate comply requirement study . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>